Ketotifen effectively prevents mucosal damage in experimental colitis

R Eliakim, F Karmeli, E Okon, D Rachmilewitz

Abstract
The effects of ketotifen, a 'mast cell stabiliser,' on two models of experimental colitis were examined. The inflammatory response elicited by either trinitrobenzene sulphonic acid or acetic acid resulted in increased colonic synthesis of platelet activating factor, prostaglandin E\textsubscript{2}, thromboxane B\textsubscript{2}, leukotrienes B\textsubscript{4}, and C\textsubscript{4}, and myeloperoxidase activity. Intragastric administration of ketotifen 100 \(\mu\)g/100 g twice daily significantly decreased mucosal damage when given prophylactically 48 hours before the induction of colitis and then throughout the experiment. This effect was consistent in both models and was accompanied by a significant reduction in mucosal generation of platelet activating factor, prostaglandin E\textsubscript{2}, thromboxane B\textsubscript{2}, and leukotrienes C\textsubscript{4} and B\textsubscript{4}. Myeloperoxidase activity was reduced as well, reaching significance only in the acetic acid model. This study shows that both trinitrobenzene sulphinic acid and acetic acid colitis can be pharmacologically manipulated by ketotifen. The mechanism of action of ketotifen has not yet been determined. Ketotifen's potential in the treatment of active inflammatory bowel disease or in the prevention of exacerbations, or both, remains to be elucidated.

(Gut 1992; 33: 1498–1503)

The inflamed mucosa in ulcerative colitis and Crohn's disease is infiltrated by equally prominent components of neutrophils, macrophages, and lymphocytes.\textsuperscript{1,2} The presence of neutrophils along with macrophages suggests involvement of soluble chemotactic mediators causing migration of inflammatory cells into the mucosa.\textsuperscript{3,4} Mast cells are involved in both the induction and amplification of the inflammatory processes in the intestine.\textsuperscript{5} Increased numbers of activated mast cells and eosinophils are present in the active site in inflammatory bowel disease and are a component of the granuloma in Crohn's disease.\textsuperscript{6,7} We and others have recently characterised mediators involved in a model of acute and chronic granulomatous colitis induced by trinitrobenzene sulphonic acid (TNB) dissolved in ethanol and administered rectally.\textsuperscript{8} We have also established that ketotifen (Zaditen), a mast cell stabiliser, very effectively protects the gastric mucosa against damage induced by a variety of agents.\textsuperscript{9} This study aimed to assess the possible protective effect of ketotifen against the damage and inflammation in two experimental models of colitis induced by TNB and acetic acid.\textsuperscript{10}

Methods
All of the animal studies described here adhere to the standards established by the Guide for the care and use of laboratory animals.\textsuperscript{11}

COLITIS INDUCTION TNB MODEL

Male rats (Hebrew University strain), weighing 200–250 g, and fed ad libitum were used in all the studies. Inflammation of the colon was induced under light ether anaesthesia by a single intracolic administration of 0.25 ml of 50% ethanol containing 30 mg of TNB (Sigma, Israel) as previously described.\textsuperscript{12} The solution was introduced via a catheter with a 0.3 mm outer diameter placed 7 cm from the anus. The rats were killed at 24 hours, 48 hours, one, two, or three weeks after the induction of colonic injury. The colon was isolated and a 10 cm segment of the distal colon proximal to the anus was resected, its lumen rinsed with ice cold saline, and weighed. A cross section was obtained for histology and the remaining mucosa was scraped, minced, and stored at 4°C. Samples of these mucosal scrapings were processed for determination of prostaglandin E\textsubscript{2} (PGE\textsubscript{2}), thromboxane B\textsubscript{2} (TXB\textsubscript{2}), leukotriene B\textsubscript{4} (LTB\textsubscript{4}), leukotriene C\textsubscript{4} (LTC\textsubscript{4}), platelet activating factor (PAF), and myeloperoxidase (MPO) activity.

Treated rats were given ketotifen (100 \(\mu\)g/100 g) twice daily intragastrically 48, 24 or 12 hours before induction of damage, and, thereafter, twice daily until they were killed. In another experiment, ketotifen was given once two hours before the induction of damage and throughout the experiment until the rats were killed.

ACETIC ACID INDUCED COLITIS

Hebrew University strain male rats weighing 200–250 g were fasted for 24 hours. Under light ether anaesthesia, a midline abdominal incision was made, the colon was isolated, and the junction of cæcum and ascending colon ligated. Two ml of 5% acetic acid were injected into the lumen of the colon at its proximal part through a 25 gauge needle, followed by 3 ml of air which cleared most of the acetic acid from the colon.\textsuperscript{13} The midline incision was closed. Twenty four hours later the rats were killed and their colons removed and handled, as with the TNB model. Treated rats received ketotifen (100 \(\mu\)g/100 g) intragastrically, twice daily, 48 hours before the induction of damage and throughout the experiment.
Ketotifen effectively prevents mucosal damage in experimental colitis

Determination of mucosal damage
Mucosal damage was quantitated by the scoring system of Wallace et al. In this system: 0=no damage; 1=hyperaemia, no ulcers; 2=linear ulceration without hyperaemia or bowel wall thickening; 3=linear ulcer with inflammation at one site; 4=two or more sites of ulceration and inflammation; 5=two or more sites of major ulceration and inflammation, or one major site of damage extending more than 1 cm along the length of the colon; 6–10=when area of ulceration and inflammation extend more than 2 cm along the length of the colon, the score is increased by one mark for each additional cm of involvement. Mucosal damage was also measured macroscopically and expressed in mm²/rat. All scoring and measurements of damage were performed by two observers using a stereomicroscope. For the purpose of scoring, inflammation was defined as hyperaemia and thickening of the bowel wall.

Morphological Studies
Sections of colon were obtained from the same areas of the large intestine during autopsy. They were fixed in phosphate buffered formaldehyde, embedded in paraffin, and routine 5 µm sections were prepared. Tissues were routinely stained with haematoxylin and eosin and were examined by light microscopy.

Determination of MPO activity
Two hundred mg of mucosal scrapings were homogenised three times for 30 seconds at 4°C with a polytron (Kinematica GmbH, Kriens-Luzern, Switzerland) in 1·0 ml of ice cold 0·5% hexadecltrimethylammonium bromide in 50 mM phosphate buffer, pH 6·0. The polytron probe was rinsed twice with 1·0 ml of the buffer and the washings were added to the homogenate. The homogenate was then sonicated for 10 seconds, freeze thawed three times, and centrifuged for 15 minutes at 40,000 g. An aliquot of the supernatant was taken for determination of the enzyme activity, according to Bradley et al.

Determination of cyclo-oxygenase and lipo-oxygenase products
One hundred and fifty mg of mucosa were placed in preweighed tubes containing 1 ml of phosphate buffer (50 mM, pH 7·4). The mucosa was minced with scissors and centrifuged in an Eppendorf centrifuge for 10 seconds. The pellet was resuspended in 1 ml of the above buffer, incubated for one minute in a vortex mixer, indomethacin was added, and the tubes centrifuged for 60 seconds. The supernatants were kept at −20°C until radioimmunoassays were performed. The capability of the mucosa to generate PGE, TxB, LTC, and LTD was expressed as ng/g wet tissue weight.

Determination of PGE
PGE was determined by a modification of the radioimmunoassay previously reported. Briefly, 0·1 ml of the specific monoclonal anti-
PGE, was added to either 0·1 ml of standards or to the tested solutions, followed by the addition of 0·1 ml of 14PGE (4500–5500 cpm). After overnight incubation at 4°C, the antibody bound to 14PGE was separated from the free PGE, by adding 0·2 ml of the mixture of 1% activated charcoal (Fisher Scientific Co, Fair Lawn, NJ) and 0·1% Dextran T-70 (Pharmacia, Uppsala, Sweden) in PBS to each sample. After vortexing, the mixture was centrifuged at 3000 rpm for 10 minutes in a refrigerated centrifuge (4°C). The supernatant was transferred into scintillation vials to which 7 ml of scintillation fluid were added and counted for one minute each in a beta scintillator counter. PGE, (Sigma, Petach Tikva, Israel) was prepared as a stock solution (1 mg/ml absolute ethanol) and kept at −20°C. A working dilution (10 ng/ml) was freshly prepared in PBS for standards ranging from 0·15–10 ng/ml. Specific monoclonal anti-PGE, was purchased from Interpharm (Rehovot, Israel). Scintillation fluid was prepared by mixing 1:2 (vol/vol) lumax (Lumac, Landgraaf, Netherlands) and toluene (Sigma). TxB, values were determined via a commercial radioimmunoassay kit (RIA) (Amersham, England).

Measurement of LTB
LTB, immunoreactivity was determined by a RIA kit (Amersham, TRK 940). The assay combines the use of a high specific activity leukotriene B, tracer, an antiseraum specific for LTB, (cross reactivity 100%) and a leukotriene standard (range 1–6 to 200 pg/tube). The specific binding of tracer is 42.5%, non-specific binding 2.4%. Fifty per cent B/Bo displacement is obtained with 15 µg/tube and 90% B/Bo displacement with 2·2 pg/tube of LTB.

Measurement of cysteinyl leukotrienes
Monoclonal rat antileukotrienes (C₄, D, and E) were used for the quantification of cysteinyl containing leukotrienes by RIA. The monoclonal rat antileukotrienes reacts specifically with LTC, LTD, and LTE, using dextran coated charcoal RIA. It shows the following cross reactivity in competitive RIA: per cent cross reactivity at 50% displacement for LTE, <2, LTD, <1, LTC, = 100, LTD, and LTE, >80. The buffer used in RIA is phosphate buffer, 10 mM, pH 7·4 containing 130 mM NaCl, 0·1% Na₂, and 3% normal horse serum. The working dilution for the monoclonal antileukotriene was 1:1000. Standard stock solutions of leukotriene (10 µg/ml) were prepared in absolute ethanol. Working standard was diluted in phosphate buffer to a concentration of 10 ng/ml and further doubling dilutions were prepared (range from 10 ng/ml to 0·078 ng/ml). Radiolabelled leukotriene, a fresh solution of 50000–100000 dpm/ml of tritiated leukotriene, was prepared in phosphate buffer. Dextran coated charcoal was prepared as follows: 1% (w/v) Norit A activated charcoal and 0·1% (w/v) dextran T-70 in buffer without horse serum. The scintillant used was toluene:lumax (2:1).

RIA was performed as follows: One hundred µl of either standard or sample buffer were
pipetted into assay tubes and 100 μl of antibody was added to all tubes except for total and blank tubes. The tubes were incubated at 4°C for 30 minutes. One hundred μl tritiated leukotriene were added to all tubes and incubated at 4°C overnight. Two hundred μl cold buffer was added, followed by 200 μl dextran coated charcoal solution, excluding the total tube to which 200 μl buffer was added. The tubes were vortexed, incubated at 4°C for 10 minutes, and centrifuged in a refrigerated Beckman centrifuge at 3000 rpm for 10 minutes. The supernatant was transferred to scintillation vials to which 7 ml scintillation fluid was added and was counted in a Kontron liquid scintillation spectrometer.

**Platelet preparation**
Fifty ml of rabbit venous blood were collected into Falcon tubes, mixed with 1 ml 0.2 M ethylenediaminetetraacetic acid and centrifuged for 20 minutes at 1600 rpm. Plasma was transferred to another tube and centrifuged for 15 minutes at 3000 rpm. The platelet pellet was reconstituted with a washing buffer (pH 6.5) containing 2.6 mM KCl, 1 mM MgCl₂, 137 mM NaCl, 0.2 M ethyleneglycol-bis(beta-aminoethylether)-N,N'-tetra-acetic acid, 5.5 mM glucose, and 0.25% gelatine and centrifuged for 15 minutes at 3000 rpm. The platelet pellet was resuspended in the above buffer and treated with 0.1 mM aspirin for 15 minutes at room temperature, followed by another centrifugation for 15 minutes at 3000 rpm. Platelets were resuspended in washing buffer at appropriate concentrations for the measurement of platelet aggregation.

**Aggregation assay**
PFA activity was measured by platelet aggregation using a Chrono-log Corporation aggregometer. Platelets were stirred in 400 μl buffer containing 2.6 mM KCl, 1 mM MgCl₂, 137 mM NaCl, 12 mM NaHCO₃, 1.5 mM CaCl₂, 5.5 mM glucose, 0.25% gelatine, 1 mM creatine phosphate, and 10 U/ml creatine phosphokinase (pH 7.4). Samples of 10 μl were added and aggregation recorded. WEB 2086 BS inhibited dose dependently (0.17–17 μM) the PFA induced platelet aggregation (r=0.891; y=140–8.8x).

**Statistical analysis**
Data are expressed as the mean (SEM). Statistical analysis for significant differences was performed according to the Student’s t test for unpaired data and the non-parametric Mann-Whitney U test.

**Materials**
Acetic acid (Frutarom, Israel); aspirin (Aspegic, Lab Egic, Amily, France); creatine phosphate, creatine phosphokinase, fatty acid free bovine serum albumin LTC₄, indomethacin, trinitrobenzene sulfonic acid (all from Sigma Laboratories, Israel); PAF (C18) (Bachem, Switzerland); ketotifen (Wander Ltd, Berne, Switzerland); LTB₄, H-LTC₄, (Amersham, England); LTC₄, antibody (Biomakor, Israel); TxB₂, RIA (Amersham, England).

**Results**

**TNB/ETHANOL INDUCED COLITIS**

**Mucosal damage**
Intracolonic administration of TNB/ethanol resulted in extensive haemorrhagic and ulcerative damage to the proximal colon, as reported previously. By 24 hours, the damage was localised to the distal colon, lesion score being 9.0 (0.6) and the lesion area 604 (61) mm² (Table

---

**Table I. Effect of ketotifen on trinitrobenzene sulfonic acid (TNB) induced colitis in rats killed 24 and 48 hours and 3 weeks after induction of injury (Values, mean (SEM) (range))**

<table>
<thead>
<tr>
<th>Control</th>
<th>TNB/ethanol</th>
<th>TNB/ethanol + ketotifen</th>
<th>TNB/ethanol</th>
<th>TNB/ethanol + ketotifen</th>
<th>TNB/ethanol</th>
<th>TNB/ethanol + ketotifen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>24 h</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9</td>
<td>6</td>
<td>9</td>
<td>15</td>
<td>7</td>
<td>3-0 (0-9)**</td>
</tr>
<tr>
<td>Lesion score</td>
<td>0</td>
<td>9-0 (0-6)**</td>
<td>4-8 (1-0)**</td>
<td>7-6 (0-6)**</td>
<td>3-0 (0-9)**</td>
<td>7-4 (0-7)**</td>
</tr>
<tr>
<td>Lesion area (mm²)</td>
<td>0</td>
<td>604 (61)**</td>
<td>314 (6)**</td>
<td>386 (64)**</td>
<td>85 (40)**</td>
<td>624 (98)**</td>
</tr>
<tr>
<td>Weight (g/10 cm)</td>
<td>0-7 (0-02)</td>
<td>1-4 (0-07)**</td>
<td>1-3 (0-07)</td>
<td>1-5 (0-1)</td>
<td>1-2 (0-1)</td>
<td>1-73 (0-18)**</td>
</tr>
<tr>
<td>MPO (U/g)</td>
<td>0-6 (0-06)</td>
<td>4-1 (0-65)**</td>
<td>4-7 (0-1)</td>
<td>6-4 (1-0)</td>
<td>3-2 (1-3)</td>
<td>3-0 (0-7)**</td>
</tr>
<tr>
<td>LTB₄ (ng/g)</td>
<td>0-2 (0-4)</td>
<td>4-7 (0-4)**</td>
<td>6-2 (1-0)</td>
<td>1-5 (0-1)</td>
<td>3-0 (1-0)</td>
<td>1-73 (0-18)**</td>
</tr>
<tr>
<td>LTC₄ (ng/g)</td>
<td>0-2 (0-4)</td>
<td>4-7 (0-4)**</td>
<td>6-2 (1-0)</td>
<td>1-5 (0-1)</td>
<td>3-0 (1-0)</td>
<td>1-73 (0-18)**</td>
</tr>
<tr>
<td>PAF (mg/10 mg)</td>
<td>17-3 (1-45)</td>
<td>17-3 (1-45)</td>
<td></td>
<td>17-3 (1-45)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGE₂ (mg/g)</td>
<td>79-9 (1-3)</td>
<td>18-6 (3-3)**</td>
<td></td>
<td>18-6 (3-3)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TxB₂ (μg/g)</td>
<td>0-2 (0-4)</td>
<td>0-2 (0-4)**</td>
<td></td>
<td>0-2 (0-4)**</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Significantly different from control rats p<0.05; **significantly different from TNB treated rats only at the respective time interval p<0.05 (Mann-Whitney U test); for control n=17; for control n=16.
MPO=myeloperoxidase activity; LT=leukotriene; PAF=platelet activating factor; PGE₂=prostaglandin E₂; TxB₂=thromboxane B₂.
Ketotifen effectively prevents mucosal damage in experimental colitis

The lesion area increased to 878 (206) mm² a week after induction of injury, and fell to 624 (98) mm² after three weeks, the score being 7-4 (0-7) (Table I). MPO activity paralleled the acute inflammation, reaching a peak of 6-4 (1-0) U/g 48 hours after induction of injury (Table I). Mucosal damage was accompanied by diarrhea in all the untreated rats.

Effects of ketotifen on mucosal damage

Ketotifen had no effect on the severity of mucosal damage when given two hours beforehand and continued after the induction of colonic inflammation by TNB. - lesion scores 8-9 (0-4) (n = 9) and 9-0 (0-6) (w = 6) and lesion areas 969 (97) mm² and 604 (61) mm², respectively in ketotifen treated and control rats sacrificed 24 hours after the induction of damage. In rats sacrificed 48 hours after the induction of injury, no protection by ketotifen was observed as well. In another experiment rats were given ketotifen (100 µg/100 g twice daily) 24 and 12 hours beforehand and continued after the induction of injury, and were sacrificed three days later. No significant effect was seen on the severity of mucosal damage: lesion scores 7-0 (1-6) and 7-3 (1-4) (n = 5), respectively, in the 24 and 12 hour ketotifen groups versus 7-0 (0-6) (n = 10) in the TNB group only. In contrast, ketotifen (100 µg/100 g twice daily) given intragastrically 48 hours beforehand and continued after the induction of injury, significantly decreased mucosal damage at all time intervals examined (Table I).

The protective effect of ketotifen was not accompanied by a significant reduction in MPO activity, although there was a trend towards lower MPO values after three weeks (Table I). Mucosal LTB₄, LTC₄, and TxB₂ generation were significantly reduced in ketotifen treated rats three weeks after damage induction (Table I), whereas mucosal PGE₂ generation was significantly lower only at two weeks: 28-4 (4-2) (n = 6) compared with 52-6 (6-6) in TNB treated rats (p < 0.05). Twenty four and 48 hours after damage induction, mucosal PAF values were significantly lower in ketotifen treated rats (Table I). Three weeks after the induction of damage by TNB all rats had diarrhea (defined as watery stool), compared with only 10% of rats in the group treated with ketotifen. The protective effect was not accompanied by a reduction in the wet weight of the involved segment.

Histology

Sections from the large intestine of rats sacrificed 48 hours after the induction of injury (Fig 1A) showed severe widespread ulcerations with extensive inflammatory cell exudate consisting mainly of polymorphonuclear leukocytes. The inflammatory exudate infiltrated all layers of the intestine, including the muscularis propria. Sections from the large intestine of rats treated with ketotifen showed much smaller ulcerations (Fig 1B) with a milder inflammatory response and infiltration into the lamina propria. The TNB treated rats which were followed for 21 days and killed afterwards, showed extensive and widespread ulcerations of the mucosa, as well as extensive infiltration of the inflammatory cells with production of granulation tissue (Fig 2A). On the other hand, ketotifen protected rats that were killed after 21 days showed almost normal mucosa (Fig 2B).

ACETIC ACID INDUCED COLITIS

Mucosal damage

As in the TNB model, and as previously reported, acetic acid induced extensive colitis. Twenty four hours after administration the

---

**TABLE II** Effect of ketotifen on acetic acid induced colitis in rats killed 24 hours after induction of colitis (values mean (SEM) (range))

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Acetic acid</th>
<th>Acetic acid + ketotifen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None</td>
<td>0-7 (0-02)</td>
</tr>
<tr>
<td>Weight (g/10 cm)</td>
<td>1-0 (0-1)</td>
<td>0-7-1 (5)</td>
</tr>
<tr>
<td>Lesion score</td>
<td>3-8 (0-6)</td>
<td>1-8 (0-4)</td>
</tr>
<tr>
<td>Lesion area (mm²)</td>
<td>(3-0-9)</td>
<td>(0-4)</td>
</tr>
<tr>
<td>MPO (U/g)</td>
<td>0-6 (0-1)</td>
<td>1-9 (0-3)</td>
</tr>
<tr>
<td></td>
<td>(1-0-7)</td>
<td>(1-1-2)</td>
</tr>
<tr>
<td>PGE₂ (ng/g)</td>
<td>21-1 (4-0)</td>
<td>26-0 (9-5)</td>
</tr>
<tr>
<td></td>
<td>(11-0-5)</td>
<td>(8-0-2)</td>
</tr>
<tr>
<td>LTB₄ (ng/g)</td>
<td>3-2 (0-4)</td>
<td>5-7 (0-4)</td>
</tr>
<tr>
<td></td>
<td>(1-1-2)</td>
<td>(4-4-7)</td>
</tr>
<tr>
<td>LTC₄ (ng/g)</td>
<td>2-4 (0-2)</td>
<td>1-9 (0-3)</td>
</tr>
<tr>
<td></td>
<td>(1-1-4)</td>
<td>(1-2-3)</td>
</tr>
<tr>
<td>TxB₂ (µg/g)</td>
<td>0-0 (0-02)</td>
<td>0-5 (0-02)</td>
</tr>
</tbody>
</table>

*Significantly different from control rats, p < 0.05.
**Significantly different from rats treated with acetic acid only, p < 0.05 (non-parametric Mann-Whitney U test).
†For LTC, controls n = 17.
lesion score reached 5.8 (0.6) and the lesion area was 213 (46) mm². MPO activity increased from 0.6 (0.1) U/g in normal controls to 3.7 (0.7) U/g in the acetic acid treated rats. All treated rats experienced diarrhoea.

Effects of ketotifen on mucosal damage
Pretreatment for 48 hours with ketotifen reduced the lesion area by about 85% and the lesion score by 68%. The protection provided by ketotifen was accompanied by significant decreases in diarrhoea, in mucosal MPO activity, and in PGE, and LTC, generation. Mucosal TxB, and LTB, values were similar in acetic acid treated rats regardless of pretreatment with ketotifen (Table II).

Histology
Sections of the large intestine from the rats with acetic acid induced colitis showed superficial, small mucosal ulcerations with extensive oedema accompanied only by a mild inflammatory cell infiltration (Fig 3A). Ketotifen treated rats showed almost normal mucosa without ulceration and a very mild inflammatory response (Fig 3B).

Discussion
Ketotifen is an oral tricyclic benzochlohepta-

![Figure 2: Histological appearance of rat colon 21 days after damage induction by trinitrobenzene sulphonate acid (TNB) ethanol. (A) Section from large intestine 21 days after induction of colitis by TNB. Note the extensive and deep ulceration of the mucosa (right upper corner) with the widespread inflammation penetrating deeply into the muscularis propria (left lower corner). (Haematoxylin and eosin, original magnification ×10.) (B) Section from large intestine of a ketotifen protected rat 21 days after induction of colitis by TNB. The mucosa looks normal without ulcerations with only a very mild inflammatory response confined to the mucosa. (Haematoxylin and eosin, original magnification ×10.)](http://gut.bmj.com/)

![Figure 3: Histological appearance of rat colon 24 hours after damage induction by acetic acid. (A) Sections of large intestine from a rat with colitis induced by acetic acid. Note small superficial ulceration (right upper corner) with extensive edema and only a mild acute inflammatory response. (Haematoxylin and eosin, original magnification ×10.) (B) Section from large intestine of ketotifen protected acetic acid induced colitis. Note almost normal mucosa with only very mild inflammation. (Haematoxylin and eosin, original magnification ×10.)](http://gut.bmj.com/)
Ketotifen effectively prevents mucosal damage in experimental colitis

3 MacDermott RP, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn’s disease, but despite this drawback, they are useful for testing the potential effect of experimental drugs for the treatment of non-specific inflammatory bowel disease. The results reported herein suggest exploring the potential usage of ketotifen in the prevention and treatment of inflammatory bowel disease.

Ketotifen effectively prevents mucosal damage in experimental colitis.

R Eliakim, F Karmeli, E Okon and D Rachmilewitz

Gut 1992 33: 1498-1503
doi: 10.1136/gut.33.11.1498

updated information and services can be found at:
http://gut.bmj.com/content/33/11/1498

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/